2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures

7Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.

Abstract

Preamble 31. Introduction 31.1. Scope of the Problem 31.2. Structure and Membership of the Writing Committee 51.3. Disclosure of Relationships With Industry and Other Entities 52. Methodology 52.1. Identifying Clinically Important Outcomes 52.2. Dimensions of Care 52.3. Definition and Selection of Measures 53. 2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of SCD 63.1. Target Population and Care Period 63.2. Avoiding Overlap and Ensuring Alignment With Existing Measure Sets and Guidelines 74. Measures Included in the Set 74.1. Preventive Cardiology 74.1.1. PM-1: Smoking Cessation Intervention in Patients Who Suffered SCA, Have Ventricular Arrhythmias, or Are at Risk for SCD 74.1.2. QM-1: Screening for Family History of SCD 84.1.3. QM-2: Screening for Asymptomatic Left Ventricular Dysfunction Among Individuals Who Have a Strong Family History of Cardiomyopathy and SCD 84.2. Emergency Cardiovascular Care/Resuscitation 94.2.1. Rationale for Including Population Health–Based Measures for Prevention of SCA or SCD 94.2.2. QM-3: Referring for CPR and AED Education Those Family Members of Patients Who Are Hospitalized With Known Cardiovascular Conditions That Increase the Risk of SCA (any AMI, known heart failure, or cardiomyopathy) 94.3. Heart Failure/General Cardiology 94.3.1. PM-2: Use of ICD for Prevention of SCD inPatients With Heart Failure and Reduced Ejection Fraction 94.3.2. PM-3: Use of Guideline-Directed Medical Therapy (Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker or Angiotensin-Receptor/Neprilysin Inhibitor, Beta-Blocker, Aldosterone Receptor Antagonist) for Prevention of SCD in Patients With HeartFailure and Reduced Ejection Fraction 94.3.3. PM-4: Use of Guideline-Directed Medical Therapy (Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker or Angiotensin-Receptor/Neprilysin Inhibitor, Beta-Blocker, Aldosterone Receptor Antagonist) for the Prevention of SCD in Patients With Myocardial Infarction and Reduced Ejection Fraction 104.4. Electrophysiology 104.4.1. PM-5: Documenting the Absence of …

Cite

CITATION STYLE

APA

Al-Khatib, S. M., Yancy, C. W., Solis, P., Becker, L., Benjamin, E. J., Carrillo, R. G., … Varosy, P. D. (2017). 2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Journal of the American College of Cardiology, 69(6), 712–744. https://doi.org/10.1016/j.jacc.2016.09.933

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free